You know what scare me bro? Look at CELG vs ALXN. CELG gives 5.70 in guidance while ALXN gives 5.20. Both give the same growth rate, but look at the price difference. CELG is at $106 while ALXN is at $143? There is a major disconnect there. I just put that in as an FYI since I follow ALXN and sold it last year in the $180's.
Then keep selling if your so confident, more for us. If you got it all figured out, why come here and post? Go make your millions and let us suffer.
despite the strong dollar. I would have expected the dollar to have a larger impact which shows the incredible strength of CELG's pipeline. Revlimid is a money monster. Pomalyst and Otezla are growing like a weed and exceeding my expectations. Yes, Abraxane is a bust for the most part, but I wouldn't count it out yet. It has indications in Pancreatic cancer coming next year that could be very good. I think we can write off breast cancer and lung cancer pretty much for Abraxance. We posted 21% revenue growth even with a strong dollar and EPS blew past estimates. They also spent 1.4B buying back stock near the lows in February. They made a great purchase to pull down share count at an opportune time.
Darn it. I put in a morning bid at $103 and I just missed it. Was hoping to catch the sell down before the lift off.
this is where u load up the truck with a pe of less thAN 19 how can u avoid buying the hell out of this the only negative is the politics of lets take all the profits from anything that HASTO DO WITH DRUGS
The company has good plans for 2017 but for WS this is a crystal ball . Every time they adjust the November creates a problem no matter how little is the change. . Focus externally beaten the street number in 2016 and internally focus on building 2017 and stop taking about 2017 is going to change next week
Sentiment: Strong Buy
"sharply" - ugh
Celgene Corp. cut its sales targets for next year and said 2017 profit would come in sharply lower than it previously estimated, though the biopharmaceutical company said it is on track to meet longer-term targets.
Doesn't understand WS. With these great results they are going to be penalize because they missed the number by a hair . This implies more risk . Missing the numbers even though is for hair specially in consecutive quarters is bad even the 20% phenomenal sales growth
They missed Rev by .003 on a strong dollar. Most international Companies have been missing a great deal more than that. The beat on EPS, guidance raised 2016, over $21B by 2020. What you smoking? Go ahead and sell.
Everyone knew that was coming due to the strong dollar and weaker performance from Abraxane. We have been debating that here for the past week. The big question was how the already beaten down stock reacts to the news.